Amerikaanse aandelen « Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

13.337 Posts, Pagina: « 1 2 3 4 5 6 ... 18 19 20 21 22 23 24 25 26 27 28 ... 663 664 665 666 667 » | Laatste

Omlaag ↓

[verwijderd] 21 mei 2009 14:57

vanaf waar had je die stukjes?

[verwijderd] 21 mei 2009 15:01

quote:
Antonius86 schreef:
vanaf waar had je die stukjes?

0,21 toen aangeschaft.
dacht er eergister nog aan om nog een pluk erbij te proberen op 0.18, maarja niet gedaan...
dacht toen eigenlijk dat ze eerder naar beneden zouden gaan dan naar boven

[verwijderd] 21 mei 2009 15:32

Een prima opening...

[verwijderd] 21 mei 2009 15:38

quote:
Antonius86 schreef:
Een prima opening...

gaat nu down...

welshterrier 5 21 mei 2009 15:38

ff een dump........

[verwijderd] 21 mei 2009 15:40

Zie het. Niet echt druk op de HEB markt op het moment...

[verwijderd] 21 mei 2009 16:04

quote:
Antonius86 schreef:
Zie het. Niet echt druk op de HEB markt op het moment...

volgens mij blijven we gewoon een beetje hangen hier tot de goed of afkeuring :-(

[verwijderd] 21 mei 2009 18:10

Tja afwachten!

[verwijderd] 21 mei 2009 18:13

nieuws:?

Japan's Council Awards Innovative Technology Grants for Pandemic Influenza Vaccines Adjuvanted by Hemispherx's Ampligen(r)

May 21, 2009 10:00 AM EDT

PHILADELPHIA, May 21, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex: HEB) announced that it has learned that Japan's Council for Science & Technology Policy (CSTP) awarded to the National Institute of Biomedical Innovation (NIBIO) funds to advance research with influenza vaccines utilizing a new experimental adjuvant, Ampligen(r) (Poly I: Poly C12U). The CSTP laid open in 2008 competition of industry-academia-government institutions to apply for its authorization of Innovative Technology awards. The CSTP has elected 24 applications out of 143, and authorized the research budget as "Innovative Technology". The CSTP is a cabinet office position reporting to the Prime Minister of Japan.

NIBIO's research entitled "Innovation Project for Anti-infectious vaccines in Next Generation" is aimed at the development of high-value-added vaccines for various infections such as pandemic influenza, malaria and AIDS. With regards to influenza vaccines in particular, NIBIO has worked jointly with researchers at the National Institute of Infectious Diseases (NIID), with whom Hemispherx has been collaborating in various studies. NIBIO / NIID common goal is to develop the pandemic influenza vaccine formulated with an adjuvant, Ampligen(r), an experimental therapeutic, to be administered by intranasal routes. They expect the intranasal vaccine may exert broad cross protection against the mutated viruses of pandemic influenza based on results to date.

Study of this unique vaccine preparation combined with Ampligen(r) (Poly I: Poly C12U), an experimental therapeutic, started in April 2007 under a research grant by Japan's Ministry of Health, Labor and Welfare (MHLW). The efforts in the last 2 years are now culminating in encouraging results in rodents and monkeys wherein a dramatic increase of IgA secretion was found which leads to a broadly cross-protective effect against various pandemic influenza strains.

Hemispherx indicated that a "universal vaccine", to protect potentially against shifted wild-type strains, like the swine flu strain, would need to recognize conserved sequences among different strains of influenza vaccines. "Universal vaccines" might be effectively used against shifted strains such as the current swine flu strain which is a shifted strain of HINI virus included in the trivalent seasonal vaccine. Cross-protection, such as reported in the JIID vaccine tests to date when Ampligen(r) (an experimental therapeutic) is added, is prima-facie evidence that conserved sequences may indeed be recognized with certain specific immunizing "cocktails". A further description of adjuvant technologies and regulatory considerations is discussed in the week of May 4th issue of Biocentury.

The number of swine flu confirmed cases in Japan has soared from four to 200 within days, forcing authorities to shut down schools. According to Japanese sources, the sudden rise in cases may prompt the World Health Organization to raise the pandemic alert level to the highest level of 6.

About Super Special Consortia for Innovative Technologies (Description
from CSTP's Mission Statement):
"Strategic Promotion of Innovative Technologies
Innovative Technologies
* Technologies of the world's top-level
* Technologies that would have a considerable ripple effect in the
economy
Deploy a technology development strategy for swiftly grow[ing] budding
innovative technologies into the driving force of society-wide
innovations.
Specify the potential of excellent innovative technologies and develop
them in a timely manner for creating innovations.
Provide the potential for growth by enabling restricting factors such
as a lack of resources and environmental factors etc. to be overcome
and overcome the competition that exists at a global level.
Realization of continuous economic growth and an affluent society."

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(r) and Oragens. Ampligen(r) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications; similarly, the completion of the NDA filing process with Ampligen(r) does not imply that the product will ever be approved commercially.

welshterrier 5 21 mei 2009 20:00

wat houdt het precies in? Koers reageert er niet echt op

[verwijderd] 21 mei 2009 20:07

haha volgens mij plakken ze ook overal maar het woord swine flu tussen, in de 'hoop' dat het iets met de koers doet ;-)

[verwijderd] 21 mei 2009 20:44

quote:
welshterrier schreef:
wat houdt het precies in? Koers reageert er niet echt op

Tuurlijk wel, stort helemaal in............(((

welshterrier 5 21 mei 2009 20:45

HEB - HEMISPHERX BIOPHARMA (AMEX)

Date Open High Low Last Change Volume % Change
05/21/09 1.80 1.80 1.50 1.53 -0.17 9066243 -10.00%

Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 6996550

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 2919372

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1560743

Overall Average: 96% - Buy

Price Support Pivot Point Resistance

1.70 1.20 1.70 2.20

[verwijderd] 21 mei 2009 20:46

quote:
Horoz36 schreef:
[quote=welshterrier ]
wat houdt het precies in? Koers reageert er niet echt op
[/quote]

Tuurlijk wel, stort helemaal in............(((

hahaha

ach 1 voordeel....
ook gnbt was heftig down de dag voor het goeie bericht kwam...
weet eerlijk gezegd niet of dat toen om een aproval ging by the way, maarja er is hoop ;-)

[verwijderd] 21 mei 2009 21:01

velen verwachten waarschijnlijk nabeurs of morgen berichten of aproval of niet...
en zullen misschien deel of alles 'veilig stellen' ??

bij deze koers wacht ik liever af....

[verwijderd] 21 mei 2009 21:02

quote:
roos1971 schreef:
velen verwachten waarschijnlijk nabeurs of morgen berichten of aproval of niet...
en zullen misschien deel of alles 'veilig stellen' ??

bij deze koers wacht ik liever af....

Waar zou deze heen kunnen met aproval?

[verwijderd] 21 mei 2009 21:04

quote:
Mr swordfish schreef:
[quote=roos1971]
velen verwachten waarschijnlijk nabeurs of morgen berichten of aproval of niet...
en zullen misschien deel of alles 'veilig stellen' ??

bij deze koers wacht ik liever af....
[/quote]Waar zou deze heen kunnen met aproval?

ik zou het echt niet weten, maar rond de tien dollar?
alhoewel nee dat slaat ook nergens op,ik weet het echt niet....
heb zelf een verkoop ingezet op 7.50 volgens mij....

tja je weet het niet he haha ;-)

[verwijderd] 21 mei 2009 21:06

quote:
roos1971 schreef:
[quote=Mr swordfish]
[quote=roos1971]
velen verwachten waarschijnlijk nabeurs of morgen berichten of aproval of niet...
en zullen misschien deel of alles 'veilig stellen' ??

bij deze koers wacht ik liever af....
[/quote]Waar zou deze heen kunnen met aproval?
[/quote]

ik zou het echt niet weten, maar rond de tien dollar?
alhoewel nee dat slaat ook nergens op,ik weet het echt niet....
heb zelf een verkoop ingezet op 7.50 volgens mij....

tja je weet het niet he haha ;-)

Lol dat zou wel idioot zijn....

[verwijderd] 21 mei 2009 21:08

Alles zakt nu ook een beetje met de DOW mee. Een sombere dag vandaag op de beurs.

[verwijderd] 21 mei 2009 21:10

quote:
Mr swordfish schreef:
[quote=roos1971]
[quote=Mr swordfish]
[quote=roos1971]
velen verwachten waarschijnlijk nabeurs of morgen berichten of aproval of niet...
en zullen misschien deel of alles 'veilig stellen' ??

bij deze koers wacht ik liever af....
[/quote]Waar zou deze heen kunnen met aproval?
[/quote]

ik zou het echt niet weten, maar rond de tien dollar?
alhoewel nee dat slaat ook nergens op,ik weet het echt niet....
heb zelf een verkoop ingezet op 7.50 volgens mij....

tja je weet het niet he haha ;-)
[/quote]Lol dat zou wel idioot zijn....

ehh waarom idioot? hahaha

13.337 Posts, Pagina: « 1 2 3 4 5 6 ... 18 19 20 21 22 23 24 25 26 27 28 ... 663 664 665 666 667 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 907,98 -1,53 -0,17% 14:38


Germany40^	23.142,90	+0,27%
BEL 20	4.425,79	-0,78%
Europe50^	5.471,90	-0,31%
US30^	42.642,90	-0,82%
Nasd100^	20.340,50	-1,33%
US500^	5.781,01	-1,07%
Japan225^	37.145,10	-1,45%
Gold spot	2.904,26	-0,50%
EUR/USD	1,0808	+0,16%
WTI	66,62	+0,32%